<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: This article summarizes data submitted to the U.S </plain></SENT>
<SENT sid="1" pm="."><plain>Food and Drug Administration for marketing approval of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> as injectable suspension (Vidaza, Pharmion Corporation, Boulder, CO) for treatment of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: In one phase 3 controlled trial, 191 study subjects were randomized to treatment with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> or to observation; an additional 120 patients were treated with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in two phase 2 single arm studies </plain></SENT>
<SENT sid="3" pm="."><plain>The primary efficacy end point was the overall response rate, defined as complete or partial normalization of peripheral blood counts and bone marrow blast percentages for at least 4 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In the controlled trial, the overall response rate was 15.7% in the <z:chebi fb="0" ids="2038">azacitidine</z:chebi> treatment group; there were no responders in the observation group (P &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>Response rates were similar in the two single arm studies </plain></SENT>
<SENT sid="6" pm="."><plain>During response patients stopped being red cell or platelet transfusion dependent </plain></SENT>
<SENT sid="7" pm="."><plain>Median duration of responses was at least 9 months </plain></SENT>
<SENT sid="8" pm="."><plain>An additional 19% of <z:chebi fb="0" ids="2038">azacitidine</z:chebi>-treated patients had less than partial responses, most becoming transfusion independent </plain></SENT>
<SENT sid="9" pm="."><plain>The most common adverse events attributed to <z:chebi fb="0" ids="2038">azacitidine</z:chebi> were gastrointestinal, hematologic, local (injection site), and constitutional </plain></SENT>
<SENT sid="10" pm="."><plain>There were no <z:chebi fb="0" ids="2038">azacitidine</z:chebi>-related <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: On May 19, 2004 the U.S </plain></SENT>
<SENT sid="12" pm="."><plain>Food and Drug Administration approved <z:chebi fb="0" ids="2038">azacitidine</z:chebi> as injectable suspension for treatment of patients with the following <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> subtypes: <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> or <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (if accompanied by <z:hpo ids='HP_0001875'>neutropenia</z:hpo> or <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> or requiring transfusions), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts, <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation, and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Full prescribing information is available at http://www.fda.gov/cder/foi/label/2004/050794lbl.pdf </plain></SENT>
<SENT sid="14" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> is the first agent approved for treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
</text></document>